Adding OSA to the label for tirzepatide could give a boost to the drug in what is becoming a fiercely competitive GLP-1 agonist or ‘incretin’ market, in which Lilly is already squaring off ...

Lilly now plans to file for approval to add the heart failure indication to the label for tirzepatide, which is already sold as Mounjaro for type 2 diabetes and Zepbound for obesity, later this year.

Adults on the obesity medication tirzepatide (Zepbound) lost more weight on average than those on semaglutide (Wegovy) in a head-to-head trial of the two injectables, Eli Lilly announced on Wednesday.